Tetragenetics harnesses the unique capabilities of the protozoa Tetrahymena thermophila to produce recombinant proteins for the biopharmaceutical industry. With our world-class science team, we are rapidly advancing the knowledge surrounding this important organism and discovering new and important applications for its use.

We've developed two breakthrough platform technologies TetraExpress™ and G-SOME™ and are applying them to advance several nanoparticle-based infectious disease vaccines. Our influenza program has received support from several federal agencies, including the National Institute of Allergy and Infectious Diseases (NIAID), and we've also been funded by the Bill & Melinda Gates Foundation for our project to develop a transmission blocking malaria vaccine.

Through an active partnering effort we are working with biopharmaceutical companies to leverage our SionX™ technology to overexpress human ion channel drug targets. We have developed unique capabilities to produce immunogen preparations in any of several formats that are designed to enhance antibody production against the extracellular portions of the target.